By Mill Chart
Last update: Oct 20, 2023
Take a closer look at GENMAB A/S -SP ADR (NASDAQ:GMAB), an affordable growth stock uncovered by our stock screener. NASDAQ:GMAB boasts strong growth prospects and excels in financial health indicators, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:GMAB, the assigned 8 reflects its growth potential:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:GMAB, the assigned 5 reflects its valuation:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NASDAQ:GMAB was assigned a score of 8 for health:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GMAB has achieved a 7:
More Affordable Growth stocks can be found in our Affordable Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of GMAB
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
GENMAB A/S -SP ADR
NASDAQ:GMAB (4/26/2024, 7:00:00 PM)
After market: 28.15 0 (0%)28.15
+0.69 (+2.51%)
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Genmab is buying a privately held company focused on antibody drug conjugates.
Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.
BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...